Acuta Capital Partners, LLC Immunovant, Inc. Transaction History

Acuta Capital Partners, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$30.27 - $43.79 $821,618 - $1.19 Million	-27,143 Reduced 22.72%	92,346 $2.98 Million
Q4 2023 Feb 14, 2024	SELL	$31.31 - $44.19 $297,789 - $420,291	-9,511 Reduced 7.37%	119,489 $5.03 Million
Q3 2023 Nov 14, 2023	SELL	$18.55 - $39.96 $236,605 - $509,689	-12,755 Reduced 9.0%	129,000 $4.95 Million
Q2 2023 Aug 14, 2023	BUY	$14.2 - $23.75 $2.01 Million - $3.37 Million	141,755 New	141,755 $2.69 Million
Q1 2021 May 17, 2021	SELL	$13.08 - $49.6 $3.71 Million - $14.1 Million	-283,500 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$36.36 - $52.71 $1.22 Million - $1.77 Million	33,500 Added 13.4%	283,500 $13.1 Million
Q3 2020 Nov 16, 2020	SELL	$22.61 - $38.9 $2.26 Million - $3.89 Million	-100,000 Reduced 28.57%	250,000 $8.8 Million
Q2 2020 Aug 14, 2020	BUY	$13.87 - $28.44 $4.85 Million - $9.95 Million	350,000 New	350,000 $8.52 Million

212

66.9M

2.3M

631K

Ticker IMVT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 129,077,000
Market Cap $3.55B
Description
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of mya...

Get notified when there are updates to the investment portfolio of Acuta Capital Partners, LLC, based on Form 13F filings with the SEC.

Stay updated on Acuta Capital Partners, LLC with notifications on news.